These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? Starkey K; Heufelder A; Baker G; Joba W; Evans M; Davies S; Ludgate M J Clin Endocrinol Metab; 2003 Jan; 88(1):55-9. PubMed ID: 12519830 [TBL] [Abstract][Full Text] [Related]
30. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. Bays H; Mandarino L; DeFronzo RA J Clin Endocrinol Metab; 2004 Feb; 89(2):463-78. PubMed ID: 14764748 [No Abstract] [Full Text] [Related]
31. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808 [TBL] [Abstract][Full Text] [Related]
32. [Rosiglitazone(BRL-49653)]. Yonezawa N; Oka Y Nihon Rinsho; 2001 Nov; 59(11):2195-9. PubMed ID: 11712407 [TBL] [Abstract][Full Text] [Related]
33. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. Kielian T; Drew PD J Neurosci Res; 2003 Feb; 71(3):315-25. PubMed ID: 12526021 [TBL] [Abstract][Full Text] [Related]
34. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. Wang M; Tafuri S J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906 [TBL] [Abstract][Full Text] [Related]
35. A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation. Yotsumoto T; Naitoh T; Kanaki T; Matsuda M; Tsuruzoe N Metabolism; 2003 Dec; 52(12):1633-7. PubMed ID: 14669169 [TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. Brooks DA; Etgen GJ; Rito CJ; Shuker AJ; Dominianni SJ; Warshawsky AM; Ardecky R; Paterniti JR; Tyhonas J; Karanewsky DS; Kauffman RF; Broderick CL; Oldham BA; Montrose-Rafizadeh C; Winneroski LL; Faul MM; McCarthy JR J Med Chem; 2001 Jun; 44(13):2061-4. PubMed ID: 11405642 [TBL] [Abstract][Full Text] [Related]
39. [Current topics in the regulation of prostanoids--4. The feedback regulation by PPAR-gamma]. Ohara M; Sawa T Masui; 1999 Feb; 48(2):146-51. PubMed ID: 10087822 [TBL] [Abstract][Full Text] [Related]
40. [New antidiabetic in "virtual reality". Eye to eye with insulin resistance]. MMW Fortschr Med; 2000 May; 142(19):52. PubMed ID: 10850084 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]